

Fund Manager: Richard Penny

TM CRUX UK Special Situations Fund

“ Housebuilder, Vistry has a strong public sector exposure and substantial private residential order book which we believe should partially mitigate anticipated weakness in housing markets in 2023.

Fund Performance

During Q3 2022 the TM CRUX UK Special Situations Fund returned -10.5% versus its performance comparator, IA UK All Companies return of -5.1%.* During the period a variety of factors contributed to a difficult economic and market backdrop. Central Bank intervention and the war in the Ukraine has led to rising interest rates and commodity prices, with resulting pressures on consumer demand, an inflationary environment and deteriorating sterling. Falling markets favoured defensive positioning, and currency weakness which helped international businesses over domestic ones. This was unhelpful for the funds structural bias towards mid and small sized companies. Performance this quarter was driven by sector biases caused by the macro environment rather than stock specific news.

*Source: FE 30.06.22-30.09.22 Bid-Bid in GBP, TR, net income re-invested.

Main contributors to the funds underperformance including One Savings Bank (OSB) and Vistry. OSB is a buy-to-let mortgage bank and although house prices will likely weaken into next year, we believe it should benefit, at least partially, from a firmer rental market. Housebuilder, Vistry has a strong public sector exposure and substantial private residential order book which we believe should partially mitigate anticipated weakness in housing markets in 2023.

Small-cap FD Technologies share price fell by 27% and now is at lower levels than when the transformative deal with Microsoft was signed earlier this year. Although there has been weakness amid similar US software stocks, FD Technologies had not participated in the “NASDAQ run” of the previous two years and is now incredibly undervalued. Eyewear company, Inspects was a significant faller during the quarter. Trading was about 10% weaker due to currency movements and a slow start to the Company’s lens manufacturing operation. We believe the share price fall of over 40% was somewhat of an over-reaction, and that the fundamentals of the company remain strong. We also saw a profit warning for Glantus Holdings which the fund has a small position in.

Important Information

Please note the views, opinions and forecasts expressed in this document are based on CRUX’s research and analysis at the time of publication. Before entering into an investment agreement in respect of an investment referred to in this document, you should consult your own professional and/or investment adviser. TM CRUX UK Special Situations Fund (the ‘Fund’) is a sub-fund of TM CRUX OEIC (the ‘Company’). The Company is an investment company with variable capital and is a UCITS Scheme. It is incorporated under the Open-Ended Investment Companies Regulations 2001 (‘OEIC Regulations’) in England and Wales under registry number IC001022. The Company is regulated by the FCA and was authorised on 10 December 2014. The FP CRUX UK Special Situations Fund was renamed the TM CRUX UK Special Situations Fund on 28 September 2019.

This information is only directed at persons residing in jurisdictions where the Company and its shares are authorised for distribution or where no such authorisation is required. Please read all scheme documents prior to investing. The KIID and Fund Prospectus and other documentation related to the Scheme, are available from the CRUX website. The value of an investment and the income from it can fall as well as rise and you may not get back the amount originally invested. If you invest through a third party provider you are advised to consult them directly as charges, performance and terms and conditions may differ materially than those shown on this document.

WANdisco was a standout performer with a return of 66% over the period. The business announced funding from the US, and twice confirmed new record orders. WANdisco is benefitting from the need to store huge quantities of data from wind farms, electric vehicles and smart meters. The Company clearly has improving commercial traction with Telecom Companies and Tier 1 automotive suppliers. This quarter saw a bid for Diurnal from Californian based biotech firm Neurocrine Biosciences which lead to the share price jumping.

«During the quarter »
we added back
Whitbread and
Melrose to the
portfolio, having sold
AB Foods to fund
Whitbread.

Attribution Stock Level Q2 2022

Top 5 Contributors (%)	Bottom 5 Contributors (%)
MaxCyte +0.73	Vistry -0.93
WANdisco +0.70	Inspecs -0.83
Glencore +0.60	FD Technologies -0.69
Kistos +0.55	Premier Foods -0.58
Shell +0.31	Hill & Smith -0.58

Source: Bloomberg

Transactions

During the quarter we added back Whitbread and Melrose to the portfolio, having sold AB Foods to fund Whitbread. Both of these companies were bought at similar entry levels in 2020 and were drivers of performance in the cyclical rebound that occurred.

Whitbread has a strong balance sheet and asset backing and continues to see some recovery from depressed levels of Covid trading. Their German operation may be weaker given in country problems, but the London market should see strengthening as a weak Pound and the coronation drive tourist footfall, and work patterns recover.

Melrose's share price has been impacted by prospects of a global economic recession. The announcement of a separation of the automotive and aerospace divisions should help management to realise the upside we believe exists in the shares. We also initiated a new position in Watches of Switzerland and added to our position in Barclays. We closed our positions in small caps, MP Evans and Rank Group.

Outlook

Headlines for the UK economy remain negative and have been for some time. Paradoxically although the temptation is to sell any asset listed on the UK stock market, there are three specific reasons why this is not the case. Firstly, the majority of revenues on the UK stock market are earned overseas, thus the weakness in sterling will lead to stronger profits for these companies in sterling terms. Secondly, many of the UK

Market Cap

	Fund
>£5bn	32.3%
£500m - £5bn	35.7%
<£500m	29.0%

Source: CRUX Asset Management as at 30.09.22

Important Information

Please note: Due to rounding the figures in the holdings breakdown may not add up to 100%. Unless otherwise indicated all figures are sourced from Financial Express, Datastream, State Street and CRUX Asset Management Ltd. Third party data is believed to be reliable, but its completeness and accuracy is not guaranteed.

This document has been approved under Section 21 of the Financial Services and Markets Act 2000 by CRUX Asset Management Ltd. This document is issued by CRUX Asset Management Ltd which is registered in England and Wales (Company no. 08697189) and whose registered address is 48 Pall Mall, London, SW1Y 5JG. It is authorised and regulated by the Financial Conduct Authority (FRN 623757). These figures refer to the past and past performance is not a reliable indicator of future results. The Authorised Corporate Director is Thesis Unit Trust Management Limited, Exchange Building, St John's Street, Chichester, West Sussex, PO19 1UP. Authorised and regulated by the Financial Conduct Authority.

earners in impacted sectors have already declined by 50% or more. Whilst next year will see deteriorations in underlying profit, we believe many of these businesses are now valued too low for their long-term earning power. Thirdly, notwithstanding general economic headwinds, a focussed special situations fund will always be able to find the companies that are overly discounted or can outperform in difficult market conditions. In 2020, distressed market conditions brought about the low prices that facilitated the fund's subsequent significant outperformance from larger cyclical businesses and disruptive small and mid-cap companies. We believe current depressed conditions offer a strong opportunity to buy well-run sensibly financed businesses for the long term.

Important Information

Please note: Due to rounding the figures in the holdings breakdown may not add up to 100%. Unless otherwise indicated all figures are sourced from Financial Express, Datastream, State Street and CRUX Asset Management Ltd. Third party data is believed to be reliable, but its completeness and accuracy is not guaranteed.

This document has been approved under Section 21 of the Financial Services and Markets Act 2000 by CRUX Asset Management Ltd. This document is issued by CRUX Asset Management Ltd which is registered in England and Wales (Company no. 08697189) and whose registered address is 48 Pall Mall, London, SW1Y 5JG. It is authorised and regulated by the Financial Conduct Authority (FRN 623757). These figures refer to the past and past performance is not a reliable indicator of future results. The Authorised Corporate Director is Thesis Unit Trust Management Limited, Exchange Building, St John's Street, Chichester, West Sussex, PO19 1UP. Authorised and regulated by the Financial Conduct Authority.